Italfarmaco’s EPIDYS clinical trial for Givinostat is enrolling boys age 6 and up at 40 sites around the world. See the details in Italfarmaco’s Winter 2020 community newsletter. Or join […]
In this webinar, Sarepta Therapeutics discusses their patient support program, SareptAssist, intended to support individuals through the process of starting and staying on commercial therapy. Services provided by SareptAssist include […]
Mallinckrodt Comments on its BRAVE study (A Multicenter, Randomized, Parallel Group, Double Blind, Multiple Dose, Placebo Controlled Study to Assess the Efficacy and Safety of MNK-1411 in Male Subjects 4 […]
CureDuchenne has wrapped up our 2019 Webinar Series. We are committed to delivering the most up-to-date and accurate information to the Duchenne Community and are honored to have had the […]
Suvodirsen (formerly known as WVE-210201) is an investigational stereopure oligonucleotide being developed as a potential treatment for boys with Duchenne muscular dystrophy with mutations amenable to exon 51 skipping. Wave […]
View Santhera’s Duchenne Community Letter
We will provide an update on the scientific rationale for use of vamorolone, and share some results from our open-label Long Term Extension study. The very important pivotal clinical trial […]
The Shape Therapeutics RNAfixTM editing platform uses fully human components and avoids risks associated with in vivo CRISPR-based technologies. The SAB, comprised of industry pioneers in the field of […]
AUTHOR: Romina Foster-Bonds (View Spanish Version Below) CureDuchenne has made a significant commitment to develop and maintain a biobank dedicated to Duchenne muscular dystrophy — the CureDuchenne Biobank. The CureDuchenne […]
